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Molecular Characterization and Antiviral Analyses
of Porcine Type III Interferons
Yongming Sang,1 Raymond R.R. Rowland,2 and Frank Blecha1
Type III interferons (IFNs) are a family of recently identified antiviral cytokines. One to 3 paralogs have been
identified in several species; however, little information is available about type III IFNs in pigs. We have
identified 2 porcine type III IFNs, Sus scrofa IFN-l1 (SsIFN-l1) and SsIFN-l3, and determined their tissue
expression profile and antiviral activities. Open reading frames of SsIFN-l1 and SsIFN-l3 are 576 and 588 bp,
encoding 191 and 195 amino acid preproteins, respectively. In healthy pigs, SsIFN-l3 was primarily expressed in
mesenteric lymph nodes and intestine, whereas expression of SsIFN-l1 was found in all tested tissues and was
high in mesenteric lymph nodes, intestine, and liver. Porcine cells treated with the viral mimic, dsRNA, robustly
increased SsIFN-l3 expression, with epithelial cells generally displaying the greatest response. Conversely,
dsRNA-induced mRNA expressions of SsIFN-l1, SsIFN-a1, and SsIFN-b were relatively weaker and delayed
compared with SsIFN-l3. SsIFN-l1 and SsIFN-l3 peptides exerted similar but lower antiviral potency than
SsIFN-a1 and SsIFN-b against a porcine arterivirus and an adenovirus. These findings indicate that pigs have 2
type III IFN paralogs, which have antiviral activity and may serve as targets for modulation of the porcine host–
pathogen interaction.
Interferons (IFNs) are classified into 3 families,namely types I, II, and III (Ank and others 2006; Takeuchi
and Akira 2009). A single type II IFN, ie, IFN-g, is primarily
produced by activated T and natural killer cells and is
mainly associated with adaptive immunity (Ank and others
2006; Pestka 2007). Conversely, type I and type III IFNs
consist of multiple members. For example, type I IFNs in-
clude several subtypes such as IFN-a, IFN-b, IFN-e, IFN-o,
and IFN-k and are widely expressed in nucleated cells ex-
erting early innate antiviral protection (Borden and others
2007; Pestka 2007). Type III IFNs are the most recently dis-
covered IFN family and are encoded by 1–3 functional genes
in various animal species. Designated IFN-l1, IFN-l2, and
IFN-l3 in humans, they are also known as interleukin (IL)-
29, IL-28A, and IL-28B, respectively (Ank and Paludan 2009;
Fox and others 2009).
Type III IFNs are distinct from type I IFNs in at least 4
features. First, they are encoded by genes with multiple ex-
ons (usually 5) in contrast to the single-exon genes for type I
IFNs (Fox and others 2009). Second, the peptide structure of
human IFN-l3 more closely resembles IL-22 of the IL-10
cytokine family rather than other IFNs (Gad and others
2009). Third, they use different receptors: IL-28RA/IL-10R2
rather than the IFNAR1/IFNAR2 receptors for type I IFNs
(Kotenko and others 2003; Sheppard and others 2003).
Fourth, unlike type I IFNs, which are widely expressed in
nucleated cells, type III IFNs and their receptors are promi-
nent in epithelial tissues, suggesting their involvement in
epithelial antiviral immunity (Ank and others 2008; Som-
mereyns and others 2008; Wang and others 2009). Despite
these distinctions, type III IFNs are induced through similar
signal transduction pathways as type I IFNs (Ank and others
2006; Zhang and others 2008). For example, activation of
signaling pathways mediated by Toll-like receptor (TLR)-3
and retinoic acid inducible gene I (RIG-I), which have been
well characterized to induce IFN-a/b production, also in-
duce type III IFNs in murine and human cells (Dumoutier
and others 2004; Onoguchi and others 2007; Zhou and others
2009). Further, stimulated expression and antiviral potency
of human type III IFNs have been associated with infections
by several RNA and a few DNA viruses, including hepatitis
C virus, influenza A virus, and cytomegalovirus (Ank and
others 2006; Ank and Paludan 2009). Thus, type III IFNs
comprise a group of newly identified antiviral cytokines that
are functionally similar to type I IFNs and elicit first-line
antiviral responses, especially in epithelial cells.
Annotation of available nucleic acid databases indicates
that 1–3 type III IFNs exist in most mammalian species (Fox
and others 2009). Humans have 3 type III IFNs (IFN-l1, IFN-
l2, and IFN-l3), and mice have 2 paralogs (IFN-l2 and IFN-
l3) (Ank and Paludan 2009; Fox and others 2009). However,
there is little information about type III IFNs in pigs. Because
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pigs are often used for comparative physiological and im-
munological studies and because porcine tissues and organs
are often used for xenotransplantation, we sought to deter-
mine the type III IFN profile in pigs. Here we report
the identification and initial characterization of 2 porcine
IFN-ls—information that is fundamental for comparative
investigations of type III IFNs in innate immunity.
Using bioinformatic annotation and experimental isolation
as described previously (Sang and others 2005, 2008), 2
porcine IFN-l genes, similar to human IFN-l1 and IFN-l3,
b
a
FIG. 1. Molecular identification of porcine type III interferons (IFNs). (a) Multiple sequence alignment of proproteins of
porcine (Sus scrofa, Ss) IFN-l1 and IFN-l3 to human (Homo sapien, Hs) and murine (Mus musculus, Mm) type III IFNs.
Residues with identities >50% are shaded (light shading for similar residues and dark shading for identical residues).
Predicted cleavage sites of signal peptidase on porcine type III IFNs are indicated by arrows at position 19 and 23 for SsIFN-
l1 and SsIFN-l3, respectively. The horizontal lines identify 4 a-helical regions (A to D) as predicted in SsIFN-l3. The
numbered black arrows indicate conserved cysteine residues among all or some (numbers in parentheses) subtypes of aligned
IFNs. Sequence alignment and protein predication were done with BioEdit (Hall 1999) and PredictProtein (Rost and others
2004). (b) Schematic diagram of SsIFN-l3 gene structure. Shown are predicted promoter regions (on minus strand) and a 5-
exon structure illustrated proportionally in scale (DP, distal promoter; PP, proximal promoter; E, exon; UTR, untranslated
region). The predicted transcription start site (TSS) was defined as 0 position of the sequence and the positions of 2 punitive
cis elements, potentially for IFN regulatory factors (IRF, position 383 and 491) are indicated in the predicted promoter
region. Corresponding nucleotide positions are listed under the gene streamline. Gene sequence is available from GenBank
(accession number of FJ853389). Gene structure was predicted with McPromoter (Ohler and Niemann 2001), GenomeScan
(Yeh and others 2001), and radial basis functions-transcription start site (RBF-TSS) (Mahdi and Rouchka 2009).
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were identified and designated Sus scrofa IFN-l1 (SsIFN-l1)
(GenBank accession number FJ853390) and SsIFN-l3 (Gen-
Bank accession number GQ996936), respectively. The mRNA
encoding preproteins of SsIFN-l1 and SsIFN-l3 have open
reading frames of 576 and 588 bp yielding preproteins of 191
and 195 amino acids and predicted N-terminal 19- and 23-
residue signal peptides, respectively (Fig. 1a). Similar to type
I IFNs, mature SsIFN-l peptides are predicted to have a-
helical structures consisting of 4 or 5 helices connected by
short loops. Four and 6 conserved cysteine residues exist in
SsIFN-l1 and SsIFN-l3 and are predicted to form 2 and 3
intramolecular disulfide bonds, respectively (Fig. 1a). One
and 2N-glycosylation sites were also predicted in protein
sequences of SsIFN-l1 (NWSC [one-letter amino acid nota-
tion] at positions 65–68) and SsIFN-l3 (NCSS at positions 71–
74 and NSSL at positions 111–114), respectively, indicating
that N-glycosylation is likely associated with maturation of
these IFN peptides. At the protein level, SsIFN-l1 and SsIFN-
l3 display 50%–70% identity to orthologs from other animal
species. Our discovery of SsIFN-l1 was verified by an in-
dependent mRNA entry deposited in GenBank (accession
number FJ455508). It is 99% identical to the SsIFN-l1 cDNA
sequence we deposited with 1 nucleotide mismatch, perhaps
reflecting gene polymorphism from different genotypes.
Screening genomic and cDNA sources by in silico annotation
or experimental isolation did not identify a porcine IFN-l2
ortholog. Thus, similar to mice, pigs likely have only 2 IFN-
ls. In addition, we determined the gene structure of SsIFN-
ls, as represented by SsIFN-l3 (Fig. 1b). The typical 5-exon
gene structure (Fox and others 2009) was found in SsIFN-l3
with exon 1, 3, and 5 encoding most helical regions of the
peptide (Fig. 1b). In the predicted promoter regions, there are
several potential binding sites for IFN regulatory factors
(Osterlund and others 2007) indicating potential involvement
of these transcription factors in SsIFN-l expression (Fig. 1b)
(Dumoutier and others 2004; Onoguchi and others 2007;
Zhou and others 2009).
To determine how the development of porcine IFN-ls
relates to other animal type III IFNs, a phylogenic analysis
was performed as described previously (Sang and others
2006) and it suggests that all animal type III IFNs likely arise
from a common IFN-l ancestral gene. Most IFN-l1 orthologs
clustered closely in a few leaves, whereas IFN-l2 and IFN-l3
orthologs were distributed in different leaves according to
animal species or clades (Fig. 2). This suggests that IFN-l1 is
phylogenically distant from other IFN-ls, and as IFN-l2 and
IFN-l3 diversified more recently, they are more similar. In
addition to gene diversification within an animal species,
coexistence of closely related IFN-l molecules across species
implies a recent gene cross-species conversion (Fox and
others 2009).
To examine the basal tissue expression profiles of porcine
IFN-ls, mRNA expression from 5-week-old healthy pigs
was examined using real-time reverse transcription (RT)–
polymerase chain reaction (PCR), as described previously
(Sang and others 2005). Primers used are shown in Table 1.
All animal procedures were approved by the Kansas State
University Institutional Animal Care and Use Committee.
Relative gene expression data in different tissues were nor-
malized against critical threshold (Ct) values of the house-
keeping gene (glyceraldehyde 3-phosphate dehydrogenase)
(Fig. 3) or calculated against control samples and presented
as fold increase (Fig. 4). Expression of SsIFN-l1 was found in
all tissues tested with the highest expression in mesenteric
lymph nodes, duodenum, and liver. In contrast, SsIFN-l3
was clearly expressed in mesenteric lymph nodes and duo-
denum and only marginally detectable in other tissues (Fig.
3). Collectively, porcine IFN-ls, especially IFN-l3, showed
tissue-dependent expression; higher expression was found in
the duodenum, liver, and mesenteric lymph nodes, and
much lower expression in bone marrow, skin, spleen, and
FIG. 2. Phylogenic relationship of porcine type III inter-
ferons (IFNs, bold text) and orthologs from other animal
species. The neighbor-joining tree was constructed with
CLUSTALW (Larkin and others 2007). GenBank accession
numbers of aligned orthologs are as follows: dog (Canis fa-
miliaris) IFN-l1, NP_001108325 and IFN-l3, XP_855366;
horse (Equus caballus) IFN-l1, XP_001501239 and IFN-l3,
XP_001916418; cat (Felis catus) IFN-l1, NP_001035770;
chicken (Gallus gallus) IFN-l3, NP_001121968; human (Homo
sapiens) IFN-l1, AAI26184, IFN-l2, AAN86126 and IFN-l3,
AAN86127; monkey (Macaca mulatta) IFN-l1, XP_001085768
and IFN-l3, XP_001086865; mouse (Mus musculus) IFN-l2,
AAX58714 and IFN-l3, AAX58715; opossum (Monodelphis
domestica) IFN-l3, XP_001368442; platypus (Ornithorhynchus
anatinus) IFN-l2, XP_001517931; chimpanzee (Pan troglo-
dytes) IFN-l1, XP_001135422 and IFN-l3, XP_001135462; Pig
(Sus scrofa) IFN-l1, FJ853390 and SsIFN-l3, GQ996936; rat
(Rattus norvegicus) IFN-l2, XP_001078329.
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testis. Because these tissues were from healthy animals
without clinical symptoms of viral infection, it is possible
that SsIFN-ls could be innate immune effectors stimulated
during pathogen surveillance in the intestine, liver, and
mesenteric lymph nodes. Because type III IFNs have been
reported to primarily act on epithelial cells in vivo (Ank and
others 2008; Sommereyns and others 2008; Wang and others
2009), future studies using antibodies to SsIFN-ls and their
receptors may determine whether SsIFN-l responses are
highly restricted to the epithelial barriers of these porcine
tissues.
In the next set of experiments, we investigated the regu-
latory expression of SsIFN-ls in 4 porcine cell lines stimu-
lated with synthetic dsRNA (polyinosinic:polycytidylic acid),
a well-tested molecular mimic of virus infection. Porcine cells
at 60%–80% confluence (2 days after subculture) were treated
with 10 mg/mL of dsRNA (Invivogen, San Diego, CA) for 3
and 24 h. Cells were collected and total RNA was extracted
using a Tri-Reagent procedure (Sigma-Aldrich, St. Louis,
MO). Similar to our tissue expression findings, SsIFN-l1 had
higher basal expression in mock-treated control cells (data
not shown). However, expression of SsIFN-l3 was robustly
increased by dsRNA treatment in all 4 cell lines (Fig. 4).
Among them, 2 epithelial cell lines, IPEC-J2 and PVD de-
rived from porcine intestine and vas deferens, respectively
(Sang and others 2005; Hagedorn and others 2007), showed
the highest stimulation. Upregulation of SsIFN-l1 by dsRNA
was only observed in the vas deferens epithelial cell line
(PVD). The dsRNA-stimulated expression of SsIFN-l3 in all
tested epithelial cells (PK-15, IPEC-J2, and PVD) was highest
at 3 h after treatment and sharply attenuated at 24 h (Fig. 4).
In contrast, stimulation in testis fibroblast cells (ST) was
much lower compared with IPEC-J2 and PVD cells and did
not decrease at 24 h (Fig. 4). For comparative purposes, we
also evaluated dsRNA-stimulated expression of SsIFN-a1
and SsIFN-b. In the tested cell lines, basal expressions of
SsIFN-a1 and SsIFN-b in control samples were similar to
SsIFN-l1, but *10–50-fold greater than SsIFN-l3. However,
stimulation with dsRNA significantly increased the expres-
sion of SsIFN-ls. Indeed, in most treated cells at both 3 and
24 h posttreatment, SsIFN-l3 attained levels greater than
SsIFN-a1 and SsIFN-b (Fig. 4). Others have also observed
that viral molecular mimics, including dsRNA, are stronger
stimulators for human IFN-l expression (Ank and others
2006; Zhou and others 2009). Compared with the none-
pithelial cells that were tested (ST), the 3 epithelial cell lines
originating from kidney (PK-15), intestine (IPEC-J2), and vas
deferens (PVD) all displayed dsRNA-stimulated peak ex-
pression of IFN-l3 at 3 h posttreatment, which was sharply
attenuated at 24 h. In addition, stimulated expression of IFN-
l3was robustly increased in IPEC-J2 and PVD epithelial cells
at 3 h post-dsRNA treatment (Fig. 3). Because synthetic
dsRNA is a ligand for several innate immune receptors, in-
cluding TLR-3, RIG-I, and melanoma differentiation-associ-
ated gene-5 (Takeuchi and Akira 2009), which mediate
antiviral responses by inducing type I and type III IFNs, it
Table 1. Cloning and Polymerase Chain Reaction Primers for Porcine Type III Interferons
Subtype Primer name and sequence (50–30)a Product size (bp)
SsIFN-l1 Senseb gccaccATGGCTACAGCTTGGATCGTGGT
Antisenseb TCAGATGTGCAAGTCTCCACTGGT 582
Antisenseb TCAagcgtaatctggaacatcgtatgggtaGATGTGCA
AGTCTCCACTGGT
609
Sense ACATCCACGTCGAACTTCAGGCTT
Antisense TCAGATGTGCAAGTCTCCACTGGT 209
SsIFN-l3 Senseb ACAGACATGGCCCTGGGT
Antisenseb TCAGACACACAGGTCTCCACT 596
Antisenseb TCAagcgtaatctggaacatcgtatgggtaGACACAC
AGGTCTCCACT
623
Sense AAGAGGGCCAAGGATGCCTTTGAA
Antisense AGGCGGAAGAGGTTGAACATGACA 374
aLowercase nucleic acids are added Kozak consensus sequences (Kozak 1987), or hemagglutinin-tag sequences (underlined) (Kolodziej and
Young 1991).
bCloning primers.
SsIFN, Sus scrofa interferon.
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FIG. 3. Expression of Sus scrofa interferon-l1 (SsIFN-l1)
and SsIFN-l3 in porcine tissues. Tissues were from 5-week-
old crossbred pigs without any clinical disease. Real-time
RT–polymerase chain reaction (PCR) assays were conducted
with gene-specific primers using total RNA (150 ng in 25 mL
PCR). Gene expression indexes (2DDCt) were calculated by
normalization against expression of a housekeeping gene
(glyceraldehyde 3-phosphate dehydrogenase [GAPDH]) and
average expression level of all tissues. B.M.C., bone marrow
cells; M.L.N., mesenteric lymph nodes. Data represent 2
independent experiments with similar results.
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will be informative to determine which receptor-mediated
signaling pathway is most responsible for type III IFN ex-
pression in porcine epithelial cells, and if the distribution of
receptors defines the production of type III IFN in different
cell types.
To evaluate the antiviral potency of SsIFN-l1 and SsIFN-
l3, we constructed and inserted their whole open reading
frames (ORFs) into a mammalian cell expression vector
(pcDNA3.3-TOPO; Invitrogen, Carlsbad, CA) as de-
scribed previously (Sang and others 2008). Cloning primers
are shown in Table 1. The authenticity of the inserted cDNA
was confirmed by sequencing, and the plasmids were
transfected (*70% transfection efficiency) into HEK293F
cells cultured in serum-free medium. Constitutive expression
of transfected SsIFN-l cDNA driven by the vector cytome-
galovirus (CMV) promoter was estimated to be at Ct values
of 12–14 using a real-time RT-PCR assay. SsIFN-l peptides
were collected from the cell culture medium and concen-
trated 10-fold using 2 centrifugal filters (Centricon 50,000
and 10,000 NMWL; Millipore, Billerica, MA). To evaluate the
IFN peptides, 20mL of concentrated peptides were resolved
by gel electrophoresis (NuPAGE Bis-Tris gel system; In-
vitrogen) and stained (Coomassie Blue G-250 solution; Bio-
Rad, Hercules, CA). Peptide concentrations were measured
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FIG. 4. The viralmimic, dsRNA, induces Sus scrofa interferon-
ls (SsIFN-ls) expression in porcine kidney (PK-15), testis
(ST), intestine (IPEC-J2), and vas deferens (PVD) cells. All
cells are epithelial except ST, which are fibroblasts. Cells at
60%–80% confluence (2 days after subculture) were treated
with dsRNA at 10 mg/mL for 3 or 24 h. Total RNA was ex-
tracted from cells and 1-step real-time RT–polymerase chain
reaction assays were conducted as in Fig. 3. Data are
mean standard error of mean; n¼ 3; **P< 0.01 and
***P< 0.001.
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FIG. 5. Porcine interferon-ls (IFN-ls) induce antiviral
protection against porcine reproductive and respiratory
syndrome virus (PRRSV) and adenovirus in porcine cells.
Porcine alveolar macrophages (A) and PK-15 (B) cells were
cultured in flat-bottomed 96-well plates and 10mL of serially
diluted (1:10 to 1:106 dilutions of initial concentrated pep-
tides at 10 mg/mL) IFN-l peptides were added to wells with
90mL of predispensed fresh medium containing each virus.
Shown here is antiviral protection of tested IFN peptides at a
102 dilution (0.1 mg/mL). Negative and positive control wells
included substitution of 10mL of IFN-l peptides with (1)
Medium: medium collected from mock-transfected cells, (2)
Anti-l1 or Anti-l3: medium collected from cells transfected
with Sus scrofa interferon (SsIFN-l) genes constructed in
antisense orientation, and (3) IFN-a1 or IFN-b: positive
controls at 0.1 mg/mL. Protective activity of IFNs on viral
infections was examined using immunostaining for PRRSV-
AMs (24 h postinfection) (Sang and others 2008) and detec-
tion of green fluorescent protein-labeled adenovirus (60 h
postinfection) using fluorescent microscopy. Percentage of
protection was calculated based on the ratio of virus-positive
cells versus total cells. Approximately 2,000 cells were eval-
uated in each treatment. Data are mean standard error of
mean; n¼ 6, *P< 0.05; n¼ 3, ***P< 0.001.
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with a micro bicinchoninic acid protein assay (Pierce, Rock-
ford, IL) and adjusted to 10 mg/mL. Apparent molecular
weights of SsIFN-l1 and SsIFN-l3 were *30 and 35 kDa,
respectively. Authenticity of IFN-l peptides was verified
by incorporation of a hemagglutinin (HA) tag into their
C-termini and staining using an immunoblotting procedure
(Sang and others 2005) with an anti-HA monoclonal anti-
body (data not shown). The antiviral potency of over-
expressed SsIFN-l peptides was examined in 2 porcine cells,
primary alveolar macrophages and a kidney epithelial cell
line (PK-15), against an arterivirus, porcine reproductive and
respiratory syndrome virus (PRRSV), and an adenovirus,
respectively. In brief, cells were cultured in flat-bottomed 96-
well plates and 10mL of IFN peptides serially diluted (1:10 to
1:106 dilutions of initial concentrated peptides at 10 mg/mL)
was added to each well with predispensed 90mL of fresh
medium containing the indicated virus. Virus titers for in-
fections were at a multiplicity of infection (MOI) of 0.1 tissue
culture infections dose (TCID50)/mL for PRRSV and ade-
novirus. Negative and positive control wells included sub-
stitution of 10 mL of IFN-l peptides with (1) minimum
essential medium (MEM): medium collected from mock-
transfected cells, (2) antisense constructs: medium collected
from cells transfected with pcDNA3.3-antisense genes, and
(3) IFN-a1 or IFN-b: positive controls at 0.1 mg/mL. The
protective activity of IFNs against viral infections was de-
termined using immunostaining (PRRSV, 24 h postinfection)
and expression of fluorescent proteins (adenovirus, 60 h
postinfection) (Sang and others 2008). SsIFN-l1 and SsIFN-
l3 (102 dilution; 0.1 mg/mL) afforded *40% and 20% pro-
tection, respectively, against PRRSV infection in alveolar
macrophages (Fig. 5A). The antiviral effect of both porcine
IFN-ls was comparably weaker than the positive controls of
SsIFN-a1 and SsIFN-b, which suppressed PRRSV infection
in alveolar macrophages to *80%. Negative controls that
were used (cells treated with medium collected from non-
transformed cells or from cells transformed with plasmids
containing SsIFN-l1 and SsIFN-l3 in antisense orientation)
showed slight or no suppression of PRRSV infection (Fig.
5A). The antiviral activity of SsIFN-l1 and SsIFN-l3 against
adenovirus in PK-15 cells was *2-fold higher than that
against PRRSV in alveolar macrophages. Protection of PK-15
cells against adenovirus by SsIFN-a1 and SsIFN-b was
similar to protection observed in PRRSV-infected alveolar
macrophages, ie, *80%–90% (Fig. 5B). However, at a lower
concentration (103 dilution), SsIFN-l1 and SsIFN-l3 only
had marginal protection, whereas SsIFN-a1 and SsIFN-b
persisted with 80%–90% protection against adenovirus in-
fection until 105 dilution (data not shown). We also tested
the anti-PRRSV potency of SsIFN-l1 and SsIFN-l3 in
MARC-145 cells, a monkey model cell line for PRRSV rep-
lication and titration (Sang and others 2008). Using 10-fold
serial dilution, we determined that SsIFN-l1 at 0.01 mg/mL
provided nearly full protection against PRRSV, which was
comparable to SsIFN-b. Conversely, a similar concentration
of SsIFN-l3 only had partial (*20%) protective activity on
MARC-145 cells (data not shown). Thus, although the 2
porcine type III IFNs had lower antiviral potency than por-
cine type I IFNs, they did induce antiviral protection in
different porcine cells against PRRSV or adenovirus. This is
similar to data with human type III IFNs that exerted similar
but weaker antiviral activity than IFN-a and IFN-b (Meager
and others 2005).
In summary, we have identified the primary, if not all,
members of the porcine type III IFN family. Porcine IFN-ls
appear to display a tissue/cell type-dependent expression
profile and exert similar but weaker antiviral activity than
type I IFNs. The direct antiviral activity of porcine IFN-ls in
porcine cells may indicate their potential for modulating
antiviral immunity in pigs.
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